Bentley Pharmaceuticals Elects Two New Directors and Adjourns Annual Stockholders' Meeting

Bentley Pharmaceuticals Elects Two New Directors and Adjourns
Annual Stockholders' Meeting 


EXETER, N.H., June 8  /PRNewswire-FirstCall/ -- Bentley Pharmaceuticals, Inc.
(NYSE:BNT), a specialty pharmaceutical company focused on advanced
drug-delivery technologies, which also manufactures and markets generic and
branded products in Europe, announced today that stockholders elected two new
members to three-year terms on Bentley's Board of Directors.  Those elected to
the Board are F. Ross Johnson, the Chairman and Chief Executive Officer of RJM
Group and the former Chairman of RJR/Nabisco Inc., and Edward J. Robinson, the
former President, Chief Operating Officer and Chief Financial Officer of Avon
Products, Inc.

James R. Murphy, Bentley's Chairman and CEO, commented, "We are pleased and
privileged to welcome Messrs. Johnson and Robinson to our board.  Their
extensive experience will add further depth to our board of directors."

After the election of the directors, the annual meeting of stockholders was
adjourned to allow continued voting on proposals to amend and restate Bentley's
restated certificate of incorporation, some of which have not yet received
sufficient votes in favor.  The adjourned meeting will reconvene to vote on the
proposals to amend and restate Bentley's restated certificate of incorporation
at 4:00 p.m. Eastern time on Friday, June 11, 2004 at Bentley's corporate
headquarters located at Bentley Park, 2 Holland Way, Exeter, New Hampshire.

Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
advanced drug delivery technologies and pharmaceutical products. Bentley's
proprietary drug technologies enhance or facilitate the absorption of
pharmaceutical compounds across various membranes. Bentley also manufactures
and markets a growing portfolio of generic and branded pharmaceuticals in
Europe for the treatment of cardiovascular, gastrointestinal, infectious and
neurological diseases through its subsidiaries, Laboratorios Belmac,
Laboratorios Davur and Laboratorios Rimafar; and manufactures and sells active
pharmaceutical ingredients through its subsidiary, Bentley A.P.I.

Copies of Bentley Pharmaceuticals' press releases and other information may be
obtained through Bentley's web site at http://www.bentleypharm.com/. 

DATASOURCE: Bentley Pharmaceuticals, Inc.



CONTACT:  Michael D. Price, Vice President, Chief Financial Officer of

Bentley Pharmaceuticals, Inc., [phone]; or Jonathan Birt of Financial

Dynamics, [phone], for Bentley Pharmaceuticals, Inc. 



Web site:  http://www.bentleypharm.com/ 

Copyright